CORRECTION

Correction: Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

In this article (Cancer Discov 2015;5:1271–81), which was published in the December 2015 issue of Cancer Discovery (1), the author list is incomplete as it appears in print. The complete author list, along with corresponding affiliations, is provided below.

Eunice L. Kwak1,2, Leanne G. Ahronian1,2, Giulia Siravegna3,4, Benedetta Mussolin3,4, Darrell R. Borger5, Jason T. Godfrey1,2, Nicholas A. Jessop5, Jeffrey W. Clark1,2, Lawrence S. Blaszkowsky1,2, David P. Ryan1,2, Jochen K. Lenneer6, A. John Iafrate3, Alberto Bardelli3,4, Theodore S. Hong3,6, and Ryan B. Corcoran1,2

1Massachusetts General Hospital Cancer Center, Boston, Massachusetts. 2Department of Medicine, Harvard Medical School, Boston, Massachusetts. 3Department of Oncology, University of Torino, Torino, Italy. 4Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy. 5Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 6Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Accordingly, the authors’ contributions section as it appears in print is incomplete. The now-included authors are credited with those contributions listed alongside their names below.

Darrell R. Borger: Conception and design; Development of methodology; Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.); Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis); Writing, review, and/or revision of the manuscript; Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases).

Nicholas A. Jessop: Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.); Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases).

The disclosure of potential conflicts of interest statement as it appears in print remains unchanged.

The online version of the article has been changed to reflect the content of this correction. The authors regret these omissions.

REFERENCE


Published OnlineFirst November 21, 2016. doi: 10.1158/2159-8290.CD-16-1271

©2016 American Association for Cancer Research.
Correction: Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in *MET*-Amplified Esophagogastric Cancer


Access the most recent version of this article at: doi:10.1158/2159-8290.CD-16-1271

This article cites 1 articles, 1 of which you can access for free at: http://cancerdiscovery.aacrjournals.org/content/6/12/1402.full#ref-list-1

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/6/12/1402. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.